- Conditions
- High-risk HPV Infection and Biopsy-proven CIN1
- Interventions
- R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7
- Biological
- Lead sponsor
- PDS Biotechnology Corp.
- Industry
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Port Jefferson, New York • The Bronx, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1057–1080
of 3,448
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Fabry Disease
- Interventions
- migalastat HCl
- Drug
- Lead sponsor
- Amicus Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Decatur, Georgia • Bethesda, Maryland + 2 more
- Conditions
- Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study, positron emission tomography
- Drug · Other · Procedure
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • San Antonio, Texas
- Conditions
- Schizophrenia
- Interventions
- AQW051, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- Major Depressive Disorder
- Interventions
- Warfarin, LY2216684
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- MT-0169
- Drug
- Lead sponsor
- Molecular Templates, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
- Conditions
- Cancer, Neuroendocrine, Ovarian Cancer, Colon Cancer
- Interventions
- JI-101, Everolimus
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Tiotropium bromide inhalation solution, Placebo
- Drug
- Lead sponsor
- Nephron Pharmaceuticals Corporation
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Rock Hill, South Carolina
- Conditions
- Cyanide Poisoning
- Interventions
- Stabilized Isoamyl Nitrite (SIAN)
- Drug
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Knoxville, Tennessee • Austin, Texas
- Conditions
- Adrenal Cortex Neoplasms
- Interventions
- XR9576 (Tariquidar)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI)
- Interventions
- Prasugrel, Clopidogrel
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Arthritis, Psoriatic
- Interventions
- Placebo, RO5310074
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Anniston, Alabama • Los Angeles, California • Miami, Florida + 3 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil Palmitil
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- MYK-461
- Drug
- Lead sponsor
- MyoKardia, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Cypress, California • Stanford, California + 4 more
- Conditions
- APDS
- Interventions
- Leniolisib
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Standford, California • Atlanta, Georgia + 1 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Oxytocin
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Biopsy, Osimertinib, Triptolide Analog
- Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Polycythemia Vera (PV)
- Interventions
- DISC-3405
- Drug
- Lead sponsor
- Disc Medicine, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 11 more
- Conditions
- Thyroid Cancer
- Interventions
- Vemurafenib (All Groups), Vemurafenib (Post Surgery) - Group A + C, Post Surgery - Group B
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors
- Interventions
- MEDI9253, Durvalumab
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- St Louis, Missouri • Buffalo, New York • New York, New York + 1 more
- Conditions
- Venous Thromboembolism (VTE), Pulmonary Embolism, Deep Vein Thrombosis (DVT)
- Interventions
- Edoxaban, Standard of Care
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 22
- States / cities
- Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- warfarin
- Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hematopoietic Syndrome Due to Acute Radiation Syndrome
- Interventions
- HemaMax, Placebo
- Biological · Drug
- Lead sponsor
- Neumedicines Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- VAY736, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 4 more